MENU
+Compare
KROS
Stock ticker: NASDAQ
AS OF
Apr 24, 04:59 PM (EDT)
Price
$14.41
Change
+$0.11 (+0.77%)
Capitalization
563.41M

KROS Keros Therapeutics Forecast, Technical & Fundamental Analysis

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs... Show more

KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for KROS with price predictions
Apr 23, 2025

KROS in upward trend: price rose above 50-day moving average on April 10, 2025

KROS moved above its 50-day moving average on April 10, 2025 date and that indicates a change from a downward trend to an upward trend. In of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 10, 2025. You may want to consider a long position or call options on KROS as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for KROS just turned positive on April 10, 2025. Looking at past instances where KROS's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for KROS crossed bullishly above the 50-day moving average on April 15, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

KROS broke above its upper Bollinger Band on April 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for KROS entered a downward trend on April 09, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.015) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (151.515) is also within normal values, averaging (252.992).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

KROS is expected to report earnings to rise 4.39% to -119 cents per share on May 01

Keros Therapeutics KROS Stock Earnings Reports
Q1'25
Est.
$-1.19
Q4'24
Beat
by $0.22
Q3'24
Missed
by $0.13
Q2'24
Beat
by $0.01
Q1'24
Beat
by $0.12
The last earnings report on February 26 showed earnings per share of -113 cents, beating the estimate of -136 cents. With 488.76K shares outstanding, the current market capitalization sits at 563.41M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on treatments for rare muscle diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1050 Waltham Street
Phone
+1 617 314-6297
Employees
136
Web
https://www.kerostx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VIOAX9.19N/A
N/A
VELA Income Opportunities A
FMPAX25.18N/A
N/A
Fidelity Advisor Mid Cap Value A
PWTYX46.56N/A
N/A
UBS US Allocation P
LCBEX30.04N/A
N/A
ClearBridge Dividend Strategy IS
QICLX14.46N/A
N/A
AQR International Multi-Style I

KROS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with INZY. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+2.95%
INZY - KROS
43%
Loosely correlated
-4.84%
AXON - KROS
43%
Loosely correlated
+3.82%
RAPT - KROS
39%
Loosely correlated
+5.93%
DNLI - KROS
39%
Loosely correlated
+1.85%
VERV - KROS
39%
Loosely correlated
+3.81%
More